| SRE |
Report |
Q2 2026 Adjusted EPS |
BEAT |
pred ~$1.08 vs. cons $1.01 (Q2'26; PY $0.89) |
MEDIUM |
| SRE |
Report |
Sempra Texas (Oncor) segment earnings |
BEAT |
pred ~$300M vs. cons ~$260M (PY $208M; rate-case catch-up surcharge back to Jan 1) |
MEDIUM |
| SRE |
Report |
Q2 2026 Revenue |
IN-LINE |
pred ~$3.16B vs. cons $3.14B |
LOW |
| SRE |
Guide |
FY2026 Adjusted EPS guidance |
UNCHANGED |
guide reaffirm $4.80–$5.30 (mid ~$5.05) vs. cons $5.06 (FY2026) |
MEDIUM |
| SRE |
Guide |
FY2027 Adjusted EPS guidance |
UNCHANGED |
guide reaffirm $5.10–$5.70 (mid ~$5.40) vs. cons $5.42 (FY2027) |
MEDIUM |
| SRE |
Guide |
Long-term EPS growth rate |
UNCHANGED |
guide reaffirm 7–9% vs. cons ~7–9% (thru 2029) |
HIGH |
| SRE |
Guide |
SI Partners (KKR 45%) sale close timing |
LOWER |
guide ~Q3 2026 close vs. cons ~Q2–Q3 2026 (timing drift confirmed w/ CFO transition) |
MEDIUM |
| SRE |
Guide |
Texas incremental CapEx bucket update |
UNKNOWN |
guide potential +$9–10B add vs. cons ~$0 quantified (2026–2030 out-period) |
LOW |
| SRE |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
LOW |
| SRE |
Return |
5-day cumulative residual |
+0.5% (FADE) |
Likely EPS/Texas beat is driven by the one-time Oncor rate-case catch-up surcharge (Jan 1 back-recognition) while FY2026/2027 guides are only reaffirmed — implicit out-period math means H2 is a touch lighter, so no upward revisions follow the beat. Initial relief bounce on a beaten-up, low-positioning name fades as the SI close slips to Q3, the CFO transition adds overhang, and any incremental Texas CapEx update stays qualitative. |
LOW |